SCHEMBL4846041

SCHEMBL4846041

CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1CN2c1ccc2cc([N+](=O)[O-])ccc2n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.51
HDAC1 Q13547 2/20 0.45
ALDH1A1 P00352 3/20 0.43
HTR3E A5X5Y0 1/20 0.43
HTR3B O95264 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
SLC6A4 P31645 1/20 0.43
CYP2C19 P33261 1/20 0.43
THPO P40225 1/20 0.43
HTR3A P46098 1/20 0.43
HTR3D Q70Z44 1/20 0.43
HTR3C Q8WXA8 1/20 0.43
GPR119 Q8TDV5 1/20 0.42
GRM2 Q14416 1/20 0.42
LMNA P02545 2/20 0.42
PMP22 Q01453 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
RET P07949 2/20 0.41
HSD11B1 P28845 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30261840 0.83 HDAC1 (0.57) PARP1HDAC1ALDH1A1CYP2C19GPR119
SCHEMBL22570167 0.83 HDAC1 (0.57) PARP1HDAC1ALDH1A1CYP2C19GPR119
SCHEMBL30533239 0.80 PARP1 (0.53) PARP1HDAC1GPR119GRM2RET
SCHEMBL29967319 0.80 PARP1 (0.53) PARP1HDAC1GPR119GRM2RET
SCHEMBL4846555 0.80 ALDH1A1 (0.51) PARP1ALDH1A1HTR3EHTR3BCYP1A2
SCHEMBL2718590 0.80 MAPT (0.54) PARP1HDAC1ALDH1A1GPR119LMNA
SCHEMBL30984738 0.80 MAPT (0.54) PARP1HDAC1ALDH1A1GPR119LMNA
SCHEMBL1887804 0.80 MAPT (0.54) PARP1HDAC1ALDH1A1GPR119LMNA
SCHEMBL18186221 0.79 HSD11B1 (0.44) PARP1HDAC1ALDH1A1CYP1A2CYP3A4
SCHEMBL18186222 0.79 HSD11B1 (0.44) PARP1HDAC1ALDH1A1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7329754-B2 2,5-diazabicyclo[2.2.1]heptane derivatives NEUROSEARCH A/S (DK) 2008-02-12 US disclosed
EP-1368348-B1 NOVEL 2,5-DIAZABICYCLO(2.2.1)HEPTANE DERIVATIVES NEUROSEARCH AS (DK) 2005-01-19 EP disclosed
US-20040181069-A1 Novel 2,5-diazabicyclo[2.2.1]heptane derivatives DANPET AB (SE) 2004-09-16 US disclosed
EP-1368348-A1 NOVEL 2,5-DIAZABICYCLO(2.2.1)HEPTANE DERIVATIVES NEUROSEARCH A/S (DK) 2003-12-10 EP disclosed
WO-2002070522-A1 NOVEL 2,5-DIAZABICYCLO[2.2.1]HEPTANE DERIVATIVES NEUROSEARCH A/S (DK) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181069-A1 Novel 2,5-diazabicyclo[2.2.1]heptane derivatives CHRNA2, CHRNB2, CHRNA10 PARP1 1579/4885HDAC1 2290/4885ALDH1A1 749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.